EGFR and non-small cell lung carcinoma: Patients with EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC) exhibit a less favorable prognosis compared to those with common EGFR mutations, with a median overall survival (mOS) of 16.5 months versus 33.0 months (13).